Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24072670 | 1.00 | TDP1 (0.63) | TDP1RAB9ANPC1NR2F2KMT2A | |
| SCHEMBL24072666 | 1.00 | TDP1 (0.63) | TDP1RAB9ANPC1NR2F2KMT2A | |
| SCHEMBL25288631 | 0.94 | TDP1 (0.68) | TDP1RAB9ANPC1NR2F2KMT2A | |
| SCHEMBL24072191 | 0.94 | TDP1 (0.68) | TDP1RAB9ANPC1NR2F2KMT2A | |
| SCHEMBL25294102 | 0.93 | TDP1 (0.66) | TDP1RAB9ANPC1NR2F2KMT2A | |
| SCHEMBL24072154 | 0.93 | TDP1 (0.66) | TDP1RAB9ANPC1NR2F2KMT2A | |
| SCHEMBL25286261 | 0.89 | TDP1 (0.78) | TDP1RAB9ANPC1NR2F2KMT2A | |
| SCHEMBL24072138 | 0.89 | TDP1 (0.78) | TDP1RAB9ANPC1NR2F2KMT2A | |
| SCHEMBL24071825 | 0.85 | TDP1 (0.66) | TDP1RAB9ANPC1NR2F2KMT2A | |
| SCHEMBL25287317 | 0.85 | TDP1 (0.66) | TDP1RAB9ANPC1NR2F2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212122-A1 | MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212122-A1 | MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES | TFAM, CS, FH | TDP1 273/4885RAB9A 839/4885NPC1 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.